Effects of Inclisiran and Statins on Vulnerable Coronary Plaques
Official title: Using OFR Software to Observe the Effects of Inclisiran Combined With Statins on the Morphology and Vascular Function of Coronary Vulnerable Plaques
Run by Nanjing First Hospital, Nanjing Medical University · NCT06338293 · Data updated 2026-11-12
This study is testing whether a combination of inclisiran and statins can improve the health of dangerous cholesterol plaques in the arteries of people with coronary artery disease.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | March 15, 2024 |
| Main results expected | June 30, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | February 14, 2025 |
| Trial ID | NCT06338293 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-80 with coronary artery lesions showing vulnerable plaques who have been on statin therapy but still have elevated LDL-C levels.
✕Probably not a fit
Patients with recent acute myocardial infarction, severe coronary artery distortions, or significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the combined effects of inclisiran and statins on the morphology and vascular function of vulnerable coronary plaques in patients with coronary artery disease. It aims to utilize advanced imaging techniques, including OCT, IVUS, and FFR, to better identify and treat these plaques. By analyzing the data from these multimodal detection methods, the study seeks to provide a clearer understanding of plaque characteristics and improve treatment outcomes. Participants will be monitored for changes in plaque morphology and function following treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with coronary artery disease, potentially stabilizing vulnerable plaques and reducing the risk of heart attacks.
How similar studies have gone: Other studies have shown promise in using multimodal imaging techniques for assessing coronary plaques, but the specific combination of inclisiran and statins in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Age 18-80 years old; 2. Coronary angiography (CAG) showed that the diameter of the primary coronary lesion was 20 \~ 70%, and the lesion was confirmed by OCT and OFR analysis, in which the target lesion contained at least one vulnerable plaque (the thinnest fibrous cap thickness was ≤65um, and the lipid core was ≥ 90), and the target vessel did not need further percutaneous coronary intervention (PCI); 3. Patients have been treated with statins for ≥4 weeks, but their LDL-C level were still ≥ 70 mg/dl (≥ 1.8 mmol/l). Exclusion criteria: 1. Acute myocardial infarction occurred in recent 30 days; 2. The target lesion of coronary artery is severely distorted and angulated; Severe left main artery lesion, chronic occlusive lesion and bifurcation lesion; 3. Previous CABG; 4. Serum triglyceride (TG) \> 500 mg/dl (\> 5.6 mmol/l); 5. Patients with severe heart failure (\< 40%) and respiratory failure; 6. Severe renal insufficiency (eGFR \< 30ml /min/1.73m2), active liver disease or severe liver damage;7. allergic to statins or inclisiran, and used PCSK9 monoclonal antibody in the past; 8. Known active infection or severe blood, metabolic or endocrine dysfunction; 9. Non-cardiac surgery is planned within 12 months; 10, can't follow the requirements of the follow-up, or researchers believe that the subjects to participate in the trial will increase the risk.
Where it's running
-
NanJing Frist Hospital
Nanjing, Jiangsu, China Recruiting
Study contacts
- Principal investigator: China Jiangsu — Nanjin First Hospital,Nanjing Medical University
- Study coordinator: Peina Meng, MD
- Email: 527114121@qq.com
- Phone: 8615805199492
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.